Reversible male contraception by targeted inhibition of serine/threonine kinase 33
Science · 2024
DOI: 10.1126/science.adl2688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2024. Verfasst von Angela F Ku und 29 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Contraceptive Agents, Male, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases, Small Molecule Libraries. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NICHD NIH HHS, Gates Foundation.
Abstract (Originalsprache)
Men or mice with homozygous serine/threonine kinase 33 ( STK33 ) mutations are sterile owing to defective sperm morphology and motility. To chemically evaluate STK33 for male contraception with STK33-specific inhibitors, we screened our multibillion-compound collection of DNA-encoded chemical libraries, uncovered potent STK33-specific inhibitors, determined the STK33 kinase domain structure bound with a truncated hit CDD-2211, and generated an optimized hit CDD-2807 that demonstrates nanomolar cellular potency (half-maximal inhibitory concentration = 9.2 nanomolar) and favorable metabolic stability. In mice, CDD-2807 exhibited no toxicity, efficiently crossed the blood-testis barrier, did not accumulate in brain, and induced a reversible contraceptive effect that phenocopied genetic STK33 perturbations without altering testis size. Thus, STK33 is a chemically validated, nonhormonal contraceptive target, and CDD-2807 is an effective tool compound.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
- Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030, USA.
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
- Promega Corporation, Madison, WI 53711, USA.
- Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
ORCID-Profile: Angela F Ku, Kiran L Sharma, Hai Minh Ta, Courtney M Sutton, Kurt M Bohren, Srinivas Chamakuri, John M Hakenjos, Ravikumar Jimmidi, Katarzyna Kent, Feng Li, Jian-Yuan Li, Chandrashekhar Madasu, Murugesan Palaniappan, Xuan Qin, Banumathi Sankaran, Yasmin M Vasquez, Jian Wang, Jennifer Wilkinson, Zhifeng Yu, Qiuji Ye, Mingxing Teng, Choel Kim, Martin M Matzuk
Förderung
- NIGMS NIH HHS
- NICHD NIH HHS
- Gates Foundation
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Ku, A. F., Sharma, K. L., Ta, H. M., Sutton, C. M., Bohren, K. M., Wang, Y., Chamakuri, S., Chen, R., Hakenjos, J. M., Jimmidi, R., Kent, K., Li, F., Li, J. Y., Ma, L., Madasu, C., Palaniappan, M., Palmer, S. S., Qin, X., Robers, M. B., …, & Matzuk, M. M. (2024). Reversible male contraception by targeted inhibition of serine/threonine kinase 33. Science. https://doi.org/10.1126/science.adl2688
Vancouver
Ku AF, Sharma KL, Ta HM, Sutton CM, Bohren KM, Wang Y, et al. Reversible male contraception by targeted inhibition of serine/threonine kinase 33. Science. 2024. doi:10.1126/science.adl2688
BibTeX
@article{Ku2024,
author = {Ku, Angela F and Sharma, Kiran L and Ta, Hai Minh and Sutton, Courtney M and Bohren, Kurt M and Wang, Yong and Chamakuri, Srinivas and Chen, Ruihong and Hakenjos, John M and Jimmidi, Ravikumar and Kent, Katarzyna and Li, Feng and Li, Jian-Yuan and Ma, Lang and Madasu, Chandrashekhar and Palaniappan, Murugesan and Palmer, Stephen S and Qin, Xuan and Robers, Matthew B and Sankaran, Banumathi and Tan, Zhi and Vasquez, Yasmin M and Wang, Jian and Wilkinson, Jennifer and Yu, Zhifeng and Ye, Qiuji and Young, Damian W and Teng, Mingxing and Kim, Choel and Matzuk, Martin M},
title = {Reversible male contraception by targeted inhibition of serine/threonine kinase 33},
journal = {Science},
year = {2024},
doi = {10.1126/science.adl2688}
}
EUVIMED